Abstract:Objective: To evaluate the efficacy and safety of injectable gatifloxacin. Methods; In this multicenter, single-blind, randomized comparative study, patients with infection of lower respiratory tract and urinary tract were allocated randomly to gatifloxacin group or levofloxacin group. In each group patients were given gatifloxacin or levofloxacin intrevenously for 3-5 d followed by oral formulation. Results: (1)The clinical effective rates (gatifloxacin vs. levofloxacin) were 92.4%(110/119) vs. 91.2%(114/ 125), being 94.296(65/69) vs. 90.296(65/72) for lower respiratory tract infections and 90.0% (45/50) vs. 92.5%(42/72) for urinary tract infections, respectively, there was no statistically significant difference between the two groups; (2)The total bacterial eradication rates were 94.0% (78/83) vs. 88.0% (81/92), being 89.2% (33/37) vs. 92.9% (39/42) for urinary tract infections, there was no statistically significant difference between the two groups; however, the bacterial eradication rate of gatifloxacin (97.8% , 45/46) was higher than that of levofloxacin (84. 3% , 43/51) in lower respiratory tract infections, the difference was statistically significant. (3)Drug-related adverse effects were 29.9% (38/127) in gatifloxacin group, higher than that in levofloxacin group 10.1% (13/129). This is due to more patients with phlebitis and gastrointestinal symptoms in gatifloxacin group than those in levofloxacin group. These drug-related events could be alleviated by slowing down the speed of infusion; the adverse effects of both groups were mild and tolerable, no discontinuation of treatment due to adverse reaction. Drug-related abnormal laboratory findings oc- carred in gatifloxacin group and levefloxacin group were 24. 8% (30 /121) and 22. 1 % (27 /112) respectively. All were mild and transient, and there was no statistically significant difference between the two groups. Conclusions: Gatifloxacin given intravenously used as initial therapy in infectious patients with systemic clinical manifestations and followed by oral administration for the completion of therapy may get satisfactory results. The clinical efficacy of gatifloxacin is as good as that of levofloxacin. The adverse reaction rate of gatifloxacin was slightly higher than that of levofloxacin, but all the reactions are mild and tolerable.

Clinical evaluation of levofloxacin sequential therapy in the treatment of 214 patients with bacterial infections

Observation on clinical effects of intravenous levofloxacin 500 mg once-daily vs 300 mg twice-daily in the treatment of lower respiratory tract bacterial infections

A Randomized,controlled Clinical Trial of Levofloxacin Versus Ceftriaxone and Azithromycin in the Treatment of Community-Acquired Lower Respiratory Tract Infections

A Randomized, Patient-Blind, Multicenter Comparison of Gatifloxacin Versus Levofloxacin in the Treatment of Lower Respiratory Tract Infections and Urinary Tract Infections

A Multicenter, Single-Blind, Randomized Comparison of Sequential Therapy of Gatifloxacin Versus Levofloxacin in the Treatment of Bacterial Infections

A Randomized Controlled Clinical Study on Levofloxacin Versus Ciprofloxacin in the Treatment of Bacterial Infections

A multicenter double-blind randomized controlled clinical study of parenteral gatifloxacin versus levofloxacin in the treatment of acute lower respiratory tract infections

Clinical evaluation of pazufloxacin and levofloxacin in the treatment of bacterial infections

A Double-Blind, Randomized Controlled Clinical Study:Gatifloxacin Vs Levofloxacin in Treatment of 98 Patients with Urinary Tract Infections

Double-blind Randomized Controlled Clinical Trial on Gatifloxacin Versus Levofloxacin Injection for Treating Acute Bacterial Infections

Levofloxacin Versus Ciprofloxacin in the Treatment of Urinary Tract Infections: Evidence-Based Analysis

Clinical Evaluation of Injectable Gatifloxacin in the Treatment of Acute Bacterial Infections

Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China

Clinical Evaluation of the Efficacy of Intravenous Levofloxacin Once-Daily in Lower Respiratory Tract Bacterial Infections of the Elderly Patients

The clinical efficacy and safety evaluation of cefazolin sodium combined with levofloxacin for acute urinary tract infection

Clinical study of lomefloxacin compared with ofloxacin in the treatment of bacterial infections

Effect of mercifloxacin and levofloxacin on urinary tract infection

A randomized multicenter clinical study of injectable levofloxacin in the treatment of acute bacterial infections

A randomized comparative study of gatifloxacin and ciprofloxacin in the treatment of bacterial infections

Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial

Meta-analysis of High-dose and Routine-dose of Levofloxacin in the Treatment of Respiratory Tract Infection